Ann: Notification of upcoming expiry of Unlisted Options, page-56

I hadn’t forgotten adv. Pharma.
But my post was about acquisitions. Advance isn’t big innovative Pharma, who’d heard of them before the announcement, answer honestly.
Look at their website and recent deals. They focus on bringing in generics, biosimilar, heritage and otherwise low tech established stuff like antibiotics and hormones., maybe that’s why they like the repurposed dimx generic. They appear to be more a good sales function house with limited or no internal R&D innovation as such. Apart from the initial down payment, how much are they contributing to rest of trial?
nothing wrong with their business model at all I should add.